# BPC-157 TB-500 FAQ: The Wolverine Blend, Answered From the Record > BPC-157 TB-500 FAQ: what the blend is, how each peptide works, angiogenesis, dosing in animals, side effects, FDA 503A status, and WADA — answered from the literature. Twenty-two direct answers on identity, mechanism, angiogenesis, dosing, safety, and legal status — each one tied to the studies or the FDA record. ## Identity and difference BPC-157 TB-500 questions cluster around one thing: this is two peptides, not one. The answers below start there. ### What is BPC-157 and TB-500? Two distinct synthetic peptides combined as a research blend. BPC-157 is a 15-amino-acid cytoprotective and angiogenic peptide (GEPPPGKPADDAGLV, ~1,419 Da). TB-500 is an N-acetylated 7-mer (Ac-LKKTETQ, ~889 Da) from the actin-binding region of Thymosin Beta-4. Different sequences, different mechanisms, paired as a stack. ### What is the Wolverine peptide blend? A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack." It is not a single chemical entity or an approved product. The term's search volume is heavily conflated with the comic-book character. ### What is the difference between BPC-157 and TB-500? BPC-157 is a 15-amino-acid gastric-juice-derived cytoprotective and angiogenic peptide acting through VEGFR2-Akt-eNOS [2]. TB-500 is a 7-amino-acid actin-binding fragment of Thymosin Beta-4 acting on cytoskeletal migration through 1:1 G-actin sequestration [3]. Different sequences, different mechanisms. ## Mechanism ### How does TB-500 work (actin / Thymosin Beta-4)? TB-500's LKKTETQ motif binds monomeric G-actin 1:1, sequestering it and regulating the cytoskeletal dynamics that drive cell migration and re-epithelialization. Structural work on Thymosin Beta-4 established this 1:1 capping mechanism at 2 angstroms [3]. ### How does BPC-157 work compared to TB-500? BPC-157 acts as a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS, nitric-oxide modulation) [2], while TB-500 acts intracellularly on actin dynamics [3]. The two work through largely non-overlapping pathways. ### Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)? Both are reported to promote angiogenesis by distinct routes in animal and cell models: BPC-157 via VEGFR2-Akt-eNOS up-regulation [2], and TB-500/Thymosin Beta-4 via endothelial migration [6]. This is preclinical, not a human combination finding. ### Why are BPC-157 and TB-500 combined (the Wolverine stack)? The rationale pairs BPC-157's cytoprotective and angiogenic signal with TB-500's actin-driven cell-migration signal as complementary mechanisms. This "synergy" is a theoretical extrapolation from each peptide's separate mechanism, not a controlled-study finding [8]. ## Evidence and efficacy ### Is there any study showing BPC-157 and TB-500 work better together (synergy)? No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together. A 2025 systematic review of BPC-157 makes no mention of TB-500 or combination use [8]. ### Are there human clinical trials on the BPC-157 + TB-500 combination? There are no controlled human trials of the combination. Human data exist only for the individual constituents and are thin: three small BPC-157 pilots, and the human "TB-500" data are actually for full-length Thymosin Beta-4 [7]. ### What is the BPC-157 and TB-500 blend used for in research? In animal models the constituents have been studied for tendon, ligament, muscle, and wound repair and for angiogenesis [1][4]. The blend itself has no controlled human efficacy data. ### Does the BPC-157 TB-500 blend help tendon and ligament injuries? In rodent models BPC-157 accelerated transected-Achilles-tendon and ligament healing [1], and Thymosin Beta-4 improved ligament and wound healing [4]. These are animal findings, not human or combination evidence. ### Does BPC-157 and TB-500 help muscle tears and recovery? Preclinical and review evidence describes musculoskeletal-repair effects for BPC-157, but recent reviews rate the evidence at the lowest tiers (level IV-V) with no clinical safety data [8]. Nothing addresses the blend in humans. ## Dosing, handling, and pharmacokinetics ### What is the half-life of BPC-157 and TB-500? BPC-157's elimination half-life was reported as under 30 minutes in animal pharmacokinetic studies. No validated half-life is established for the TB-500 fragment, and none for the blend. ### How do you reconstitute a BPC-157 / TB-500 blend (10mg)? Both are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated for research handling [7]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed. ### How often should you inject BPC-157 and TB-500? There is no validated dosing schedule for the blend. Community "loading then maintenance" protocols have no controlled-trial basis [8] and should not be presented as validated dosing. ## Safety and legal status ### What are the side effects of BPC-157 and TB-500? Long-term human safety is unknown for both constituents. The main flagged concern is a theoretical tumor and angiogenesis signal for Thymosin Beta-4 [4], and combining two unapproved peptides compounds the uncertainty [8]. ### Does TB-500 cause cancer or promote tumor growth? Thymosin Beta-4 is implicated in tumor metastasis and angiogenesis, so the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [4]. This is a flagged safety consideration, not a demonstrated human effect of the blend. ### Is TB-500 bad for your heart? Full-length Thymosin Beta-4 has been studied in cardiac-repair models and credited with regenerative activity [4], but no controlled data exist for the TB-500 fragment or the blend, so cardiovascular effects in humans are unestablished. ### Are BPC-157 and TB-500 FDA approved or banned by WADA? Neither is FDA-approved for human use; the FDA placed both in 503A Category 2 of bulk substances flagged for significant safety risks pending review [11], and both constituents are prohibited by WADA. ### Is Wolverine legal? The blend pairs two substances neither FDA-approved for human use, both in FDA 503A Category 2 [11], both WADA-prohibited; routine compounding access to the ingredients is currently restricted [12]. The status is under active FDA review with a July 2026 PCAC meeting scheduled as a discussion, not a decision [13]. ### Can you get BPC-157 from a compounding pharmacy? Routine 503A compounding-pharmacy access to BPC-157 is currently restricted: it sits in Category 2 (flagged for significant safety risks) effective September 29, 2023, which is outside the enforcement-discretion policy for Category 1 [11][12]. Lawful compounded access generally requires a prescriber evaluation, a valid prescription, and an eligible ingredient. ### What is the FDA 503A status of Wolverine? Both constituents are in FDA 503A Category 2. The FDA lists BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" among bulk substances that may present significant safety risks, effective September 29, 2023 [11]; both are on the July 23-24, 2026 PCAC agenda as candidates under evaluation [13]. --- A versus-screen reading of the BPC-157 TB-500 blend — each peptide racked against its own studies, the combination row left at NO MATCH ON RECORD, and the FDA and WADA status called before the bell, with no clinic in the corner and nothing here for sale.